دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Clinical Images: Tongue ulceration in giant cell arteritis associated with asymptomatic retinal ischemia
Max Guarda, Umar Ghaffar, Kenneth J. Warrington, Matthew J. Koster
doi : 10.1002/acr2.11544
Clinical Image: Antineutrophil cytoplasmic antibody–associated vasculitis causing compressive cervicothoracic myelopathy
Patricia Harkins, Richard Conway
doi : 10.1002/acr2.11554
Human Leukocyte Antigen B27-Negative Axial Spondyloarthritis: What Do We Know?
Atul Deodhar, Tejpal Gill, Marina Magrey
doi : 10.1002/acr2.11555
Axial spondyloarthritis (axSpA) is a chronic, immune-mediated disease characterized by inflammatory axial skeleton involvement and extra-musculoskeletal manifestations. The continuum of axSpA ranges from nonradiographic axSpA (nr-axSpA) to ankylosing spondylitis, also known as radiographic axSpA; the latter is defined by definitive radiographic sacroiliitis.
Comparative Effectiveness of First-Line Baricitinib in Patients With Rheumatoid Arthritis in the Australian OPAL Data Set
Sabina Ciciriello, Geoffrey Littlejohn, Tamas Treuer, Kathryn A. Gibson, Ewa Haladyj, Peter Youssef, Paul Bird, Catherine O'Sullivan, Tegan Smith, Claire T. Deakin, on behalf of OPAL Rheumatology
doi : 10.1002/acr2.11577
To analyze comparative treatment persistence for first-line baricitinib (BARI) versus first-line tumor necrosis factor inhibitor (TNFi) in patients with rheumatoid arthritis (RA) and for first-line BARI initiated as monotherapy versus first-line BARI initiated with at least one conventional synthetic disease-modifying antirheumatic drug (csDMARD).
Clinical Benefit of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis for Patients With and Without a Vasculitic Phenotype
Benjamin Terrier, David R.W. Jayne, Bernhard Hellmich, Jane H. Bentley, Jonathan Steinfeld, Steven W. Yancey, Namhee Kwon, Praveen Akuthota, Paneez Khoury, Lee Baylis, Michael E. Wechsler, on behalf of the EGPA mepolizumab study team
doi : 10.1002/acr2.11571
To evaluate mepolizumab's efficacy in eosinophilic granulomatosis with polyangiitis (EGPA) with and without a vasculitic phenotype.
COVID-19 Hospitalization Outcomes Among Patients With Autoimmune Rheumatic Diseases in the United States
Ahmad Khalaf, Garad Ibrahim, Spencer Goble, Marcela Kuijpers, Rawad Nasr
doi : 10.1002/acr2.11572
To investigate the outcomes of COVID-19-related hospitalizations among patients with autoimmune rheumatic diseases (ARDs) in the United States in 2020. The primary outcome was in-hospital mortality, and secondary outcomes included intubation rate, length of hospital stay (LOS), and total hospital charges (THCs).
Biologics Initiation in Rheumatoid Arthritis by Race and Ethnicity: Results From a Randomized Survey Study
Julia F. Simard, Rong Lu, Titilola O. Falasinnu, Matthew C. Baker, Saadiya Hawa, Mariani D. Deluna, Audra Horomanski, Robert M. Fairchild
doi : 10.1002/acr2.11573
To investigate whether the race and ethnicity of a patient with rheumatoid arthritis (RA) influences rheumatologists’ likelihood of choosing to initiate biologic disease-modifying antirheumatic drug (bDMARD) treatment.
Clinical Images: Tongue ulceration in giant cell arteritis associated with asymptomatic retinal ischemia
Max Guarda, Umar Ghaffar, Kenneth J. Warrington, Matthew J. Koster
doi : 10.1002/acr2.11544
Clinical Image: Antineutrophil cytoplasmic antibody–associated vasculitis causing compressive cervicothoracic myelopathy
Patricia Harkins, Richard Conway
doi : 10.1002/acr2.11554
Human Leukocyte Antigen B27-Negative Axial Spondyloarthritis: What Do We Know?
Atul Deodhar, Tejpal Gill, Marina Magrey
doi : 10.1002/acr2.11555
Axial spondyloarthritis (axSpA) is a chronic, immune-mediated disease characterized by inflammatory axial skeleton involvement and extra-musculoskeletal manifestations. The continuum of axSpA ranges from nonradiographic axSpA (nr-axSpA) to ankylosing spondylitis, also known as radiographic axSpA; the latter is defined by definitive radiographic sacroiliitis.
Comparative Effectiveness of First-Line Baricitinib in Patients With Rheumatoid Arthritis in the Australian OPAL Data Set
Sabina Ciciriello, Geoffrey Littlejohn, Tamas Treuer, Kathryn A. Gibson, Ewa Haladyj, Peter Youssef, Paul Bird, Catherine O'Sullivan, Tegan Smith, Claire T. Deakin, on behalf of OPAL Rheumatology
doi : 10.1002/acr2.11577
To analyze comparative treatment persistence for first-line baricitinib (BARI) versus first-line tumor necrosis factor inhibitor (TNFi) in patients with rheumatoid arthritis (RA) and for first-line BARI initiated as monotherapy versus first-line BARI initiated with at least one conventional synthetic disease-modifying antirheumatic drug (csDMARD).
Clinical Benefit of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis for Patients With and Without a Vasculitic Phenotype
Benjamin Terrier, David R.W. Jayne, Bernhard Hellmich, Jane H. Bentley, Jonathan Steinfeld, Steven W. Yancey, Namhee Kwon, Praveen Akuthota, Paneez Khoury, Lee Baylis, Michael E. Wechsler, on behalf of the EGPA mepolizumab study team
doi : 10.1002/acr2.11571
To evaluate mepolizumab's efficacy in eosinophilic granulomatosis with polyangiitis (EGPA) with and without a vasculitic phenotype.
COVID-19 Hospitalization Outcomes Among Patients With Autoimmune Rheumatic Diseases in the United States
Ahmad Khalaf, Garad Ibrahim, Spencer Goble, Marcela Kuijpers, Rawad Nasr
doi : 10.1002/acr2.11572
To investigate the outcomes of COVID-19-related hospitalizations among patients with autoimmune rheumatic diseases (ARDs) in the United States in 2020. The primary outcome was in-hospital mortality, and secondary outcomes included intubation rate, length of hospital stay (LOS), and total hospital charges (THCs).
Biologics Initiation in Rheumatoid Arthritis by Race and Ethnicity: Results From a Randomized Survey Study
Julia F. Simard, Rong Lu, Titilola O. Falasinnu, Matthew C. Baker, Saadiya Hawa, Mariani D. Deluna, Audra Horomanski, Robert M. Fairchild
doi : 10.1002/acr2.11573
To investigate whether the race and ethnicity of a patient with rheumatoid arthritis (RA) influences rheumatologists’ likelihood of choosing to initiate biologic disease-modifying antirheumatic drug (bDMARD) treatment.
